For the 73 patients diagnosed with EGFR‐mutant NSCLC, the primary first‐line treatment choice was surgery‐based therapy (49.3%), followed by palliative therapy (29.0%) and CRT‐based therapy at (21.7%). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.